Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “overweight” rating reissued by Piper Jaffray Companies in a report released on Tuesday, The Fly reports. They presently have a $72.00 price target on the biotechnology company’s stock, up from their previous price target of $54.00. Piper Jaffray Companies’ target price indicates a potential upside of 26.34% from the company’s previous close.

A number of other equities analysts also recently commented on ARWR. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Robert W. Baird raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their target price for the company from $39.00 to $70.00 in a research note on Monday. B. Riley raised their price target on shares of Arrowhead Pharmaceuticals from $46.00 to $59.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price target (up from $24.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Arrowhead Pharmaceuticals presently has an average rating of “Buy” and an average target price of $59.20.

Shares of ARWR stock opened at $56.99 on Tuesday. The company’s fifty day simple moving average is $40.43 and its 200-day simple moving average is $30.84. Arrowhead Pharmaceuticals has a 52 week low of $10.41 and a 52 week high of $59.72. The company has a market cap of $4.66 billion, a PE ratio of -87.68 and a beta of 1.68.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, November 25th. The biotechnology company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.03). Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. As a group, equities analysts forecast that Arrowhead Pharmaceuticals will post 0.76 earnings per share for the current fiscal year.

In related news, Director Michael S. Perry sold 85,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $30.00, for a total transaction of $2,550,000.00. Following the completion of the sale, the director now directly owns 121,000 shares of the company’s stock, valued at approximately $3,630,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael S. Perry sold 100,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the sale, the director now directly owns 121,000 shares of the company’s stock, valued at $3,496,900. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 350,104 shares of company stock valued at $10,783,025. Company insiders own 4.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Municipal Employees Retirement System of Michigan grew its holdings in Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 28,560 shares of the biotechnology company’s stock worth $805,000 after acquiring an additional 380 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 96.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 500 shares in the last quarter. United Services Automobile Association grew its holdings in Arrowhead Pharmaceuticals by 2.6% during the 2nd quarter. United Services Automobile Association now owns 20,515 shares of the biotechnology company’s stock worth $544,000 after acquiring an additional 522 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Arrowhead Pharmaceuticals by 10.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,701 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 531 shares in the last quarter. Finally, Comerica Bank grew its holdings in Arrowhead Pharmaceuticals by 0.7% during the 3rd quarter. Comerica Bank now owns 89,234 shares of the biotechnology company’s stock worth $3,291,000 after acquiring an additional 627 shares in the last quarter. 68.75% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Recommended Story: What is the yield curve?

The Fly

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.